Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-09-17

FDA Approved: EVRYSDI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Evrysdi (risdiplam) by Genentech, updating the product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EVRYSDI (risdiplam)

Snippet

SUPPL AP for EVRYSDI (RISDIPLAM)